Clinical and molecular characterization of the cisplatin-vinorelbine chemotherapeutic regimen in HER2(-) metastatic breast cancer

Despite rapid advances in treatment options, challenges still persist in advanced breast cancer. Bevacizumab is a VEGF-neutralizing antibody with proven efficacy in combination with chemotherapy for treatment of HER2 negative metastatic breast cancer (mBC). Vinorelbine, a semisynthetic vinca alkaloid, is a well-established and well tolerated chemotherapeutic in breast cancer. The combination of vinorelbine with platinum and addition of bevacizumab is relatively underreported in the literature. We propose this combination regimen as safe, well tolerated and efficacious in HER2 negative mBC patients. To model the molecular perturbations by cisplatin-vinorelbine combination, we treated the triple negative breast cancer MDA-MB-231 cell line with a combination of 7μM cisplatin + 14μM vinorelbine, in comparison to vehicle treatment. Total RNA extracted from treated cells underwent RNA-sequencing for transcriptional profiling.